Replies to post #45641 on MultiCell Technologies Inc (MCET)

[Mcetdreamer]

I could care less what you do!

I couldn't understand what you wrote/posted either!

Please see your post below.

I suggest you don't read my posts.

Besides, your's or my opinion doesn't matter, the only option that does and will matter will be the courts.


I never said I can write. But my research is solid.

I could care less if you are trying to sabotage MCET or not.

MCET is being Infringed on. I am sorry if you can't see that?



WOW this=ginormous!MCET patented-this in 2014;Sigmund seems to be the last-one in charge, you yourself posted an email from Barbara Newmin that she allegedly just does art and knows nothing nor does 80YO (tho there are 80 YO's like Buffet etc. in great mental shape still running things) husband - "ask Ed." Sorry you have great detail but the import sometimes gets lost...fill us in.

Did Sigmond stop filing disclosures in 2020 because he had this double-dealing on his agenda? And now he's been caught? HUGE recovery for MCET!

from microcapdaily Feb. 14, 21 - just a week ago, posted earlier on this board:

It is not exactly certain who is currently in charge of the Company; it could be the Company’s old CEO Jerry Newmin who is now close to 80 years old or his wife Barbara or the Company’s director, Ed Sigmond; a Partner at Sigmond & Johnson, Inc. Mr. Sigmond was also President at Kestrel Holdings, Inc., Chairman, CEO & Head-Investor Relations at The Great American Food Chain, Inc., Managing Partner & Owner at The Elbow Room, and a Director & Partner at Na Zdravi Ventures. He is/was on the Board of Directors at MultiCell Technologies, Inc.

KADCYLA sold in 2021, MCET's patented. KADCYLA next-generation antibody drug conjugates patented in 2014.

MCET also patented and owns this: ...MultiCell holds two patents on novel strategies for isolation of adult human liver cells, and cell clusters or doublets, invented by Dr. Ronald A. Faris, Senior Vice President and Chief Scientific Officer of MutliCell and Director of Research with Rhode Island Hospital. Obtaining stem cells from adult tissues avoids the ethical issues and the contamination issues associated with embryonic or fetal stem cells. Liver stem cells may play a key role in transplantation for tissue regeneration and therapeutic use including the clinical management of metabolic liver disorders and heart disease as well as potential diagnostic applications. The use of liver stem cells to treat diseases, such as Hepatitis C, may greatly enhance quality of life and avoid costly whole organ liver transplantation. MultiCell believes its patented stem cell techniques are unique within the cell therapy market.

S you ask: WHERE'S THE MONEY JERRY NEWMIN? & ED SIGMOND? WHAT DID YOU DO WITH MCET's Patented antibody drug?

KADCYLA WEBSITE: 2021

https://www.kadcyla.com/?c=kad-16e8fec9f37&gclsrc=aw.ds&&mkwid=s-dm_pcrid_407246693961_pkw_kadcyla_pmt_p&utm_source=google&utm_medium=cpc&utm_campaign=&utm_term=kadcyla&gclid=Cj0KCQiA4feBBhC9ARIsABp_nbVatz7NjV2e3yeF29S3ZbSP3qk0Uyp9JUA4JJYNP9Z7IH2ZNb8w7IUaAjWmEALw_wcB



ADC REVIEW. 2014
https://www.adcreview.com/resources-for-clinicians-and-physicians/approved-adc-antibody-drug-conjugates/approved-by-the-fda-usa/ado-trastuzumab-emtansine-kadcyla/


PR NEWSWIRE 2014
PR Newswire: news distribution, targeting and monitoring
MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application
NEWS PROVIDED BY

MultiCell Technologies, Inc.
Dec 10, 2014, 08:40 ET

WOONSOCKET, R.I., Dec. 10, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody.